Exposed Exosomes on 315: Cutting‑edge Science Is Promising — But Unregulated Shops Are Injecting Them into Veins, It Has Been Reported

315 sting finds unapproved “three‑no” exosomes sold and injected

China’s annual 315 consumer‑rights broadcast again turned a spotlight on risky health claims. It has been reported that the program and Huxiu’s follow‑up investigation found small manufacturers and clinic‑style injection points selling unapproved exosome (外泌体) products — many described as “three‑no” (三无: no production license, no approval, no quality certificate) — and reportedly administering them intravenously to elderly patients. Treatments are expensive: reporters say some clinics charge about RMB 60,000 for three sessions. Who is policing this market? Regulators are struggling to keep up.

Promising biology, premature commerce

Exosomes are tiny vesicles cells use to shuttle molecules and information to one another. In the lab they excite researchers as potential drug carriers — able to protect cargo and perhaps cross barriers such as the blood‑brain barrier — and as a safer, cell‑free alternative to some stem‑cell therapies. But that promise is still largely at the experimental and clinical‑trial stage. Celebrities have popularized the idea — Bryan Johnson (布莱恩·约翰逊) and Kim Kardashian (金·卡戴珊) have reportedly used exosome‑based products in cosmetic contexts — and social media has amplified commercial offerings from plant to fish‑derived preparations. The result: hype outpacing science.

Safety, heterogeneity and regulatory warnings

Experts warn the risks are real. Exosomes can originate from many cell types — stem cells, tumour cells, fat, dental pulp and more — and different sources yield materially different products. That heterogeneity means some preparations could be harmless, others ineffective, and some actively dangerous or infectious. It has been reported that regulators overseas have already acted: the U.S. Food and Drug Administration issued public warnings in 2019 after severe adverse events in Nebraska, and a 2023 case in Japan linked rapid cancer progression to a clinic’s stem‑cell‑derived supernatant. Academic voices — including researchers at Reading University and investigators studying tumour exosomes — describe a field rife with misuse and overclaiming. On the geopolitical stage this matters because cross‑border sourcing and international marketing complicate oversight, and regulators from Tokyo to Washington to Beijing must balance innovation with consumer protection.

A promising field harmed by premature commercialization

In short: exosomes remain a promising research direction, but commercial claims of broad‑spectrum anti‑aging or disease cures are premature and potentially dangerous. It has been reported that small workshops are already injecting unverified products into patients; the fallout could set back legitimate science and invite stricter regulation. For now patients and consumers should treat flashy offers with skepticism and demand proof — and regulators must decide how to clean up a market where science, commerce and patient safety are colliding.